ATLANTIC DIAGNOSTIC LABORATORIES RELEASES
THE FIRST BLOOD TEST FOR DEPRESSION

MDDScore™ Aids in the Diagnoses & Treatment of Major Depressive Disorder

PHILADELPHIA, PA (October 10, 2017)- Atlantic Diagnostic Laboratories (ADL) has developed a groundbreaking blood test to aid the medical community in the physical diagnoses and treatment of Major Depressive Disorder (MDD). MDDScore™ is a multiple biomarker test for depression that will help physicians in the difficult and often emotional diagnosis of MDD and assist in the selection of proper patient treatment, while improving healthcare cost management. Antidepressant drugs are among the most frequently prescribed medications in the U.S., where depression impacts some 15 million adults each year.

The MDDScore™, which uses serum concentrations of nine biomarkers, was created by ADL’s Scientific Officer, Dr. John Bilello, the former Director of Technology Development at GlaxoSmithKline.

“Given the often difficult and emotional diagnosis, many cases of depression can be missed in the busy primary care physician’s office,” said Bilello. “Biomarkers are vital scientific tools which in this case will enable health professionals to improve the accuracy of diagnosis and help match the right treatment to the right patient.”

ADL has the exclusive licensing and distribution rights to bring MDDScore™ making it the first blood test commercially available to medical professionals.

“ADL’s distribution of the MDDScore will now offer physicians the tool to test the millions of Americans suffering with major depression,” said Aaron Domenico, Chief Operating Officer of ADL. “ADL’s decades of experience in diagnostic science, and now in the launch of this blood test, demonstrates our commitment to providing physicians with tools to support their care decisions improving patient well-being.”

The test measures nine biomarker levels associated with factors such as inflammation, development and maintenance of neurons, the stress response and other key biological functions. Measurements are analyzed to produce an MDDScore™ which will tell physicians the probability that a patient has major depression.

A recent peer-reviewed study with patients diagnosed major depression and non-depressed subjects had a 93% degree of accuracy within the study population. The clinical performance of MDDScore™ has been demonstrated in clinical studies conducted with major academic
centers, such as Harvard, Massachusetts General Hospital and University of Alabama Birmingham.

Physicians and investigators involved in these studies say the MDDScore™ provides quantitative, physical proof to depression sufferers that their disease isn’t just “in their heads,” but that it’s a physical condition warranting treatment.

Interested members of the medical community can contact ADL directly to learn how to get the MDDScore™. Call toll free at 1-866-465-6763 ext. 0 or email info@adllab.net.

ADL is a full service clinical laboratory with headquarters in the suburbs of Philadelphia providing microbiology, chemistry, toxicology, immunology, virology and molecular testing in 12 states: Pennsylvania, New Jersey, Connecticut, New York, District of Columbia, Delaware, Maryland, Virginia, Florida, Ohio, Kentucky and West Virginia.

**About Atlantic Diagnostic Laboratories, LLC (ADL):**

Atlantic Diagnostic Laboratories, LLC (ADL) is a U.S.-based independent full service clinical laboratory providing microbiology, chemistry, toxicology, immunology, and virology testing used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of diseases. It has also developed niche operations based on certain types of specialized testing capabilities providing insights that empower and enable medical professionals to make better healthcare decisions. ADL is fully accredited by the College of American Pathologists (CAP) for clinical and forensic studies.